全文获取类型
收费全文 | 418篇 |
免费 | 44篇 |
国内免费 | 2篇 |
专业分类
儿科学 | 11篇 |
妇产科学 | 3篇 |
基础医学 | 69篇 |
口腔科学 | 33篇 |
临床医学 | 24篇 |
内科学 | 59篇 |
皮肤病学 | 2篇 |
神经病学 | 39篇 |
特种医学 | 18篇 |
外科学 | 47篇 |
综合类 | 1篇 |
预防医学 | 30篇 |
眼科学 | 29篇 |
药学 | 13篇 |
肿瘤学 | 86篇 |
出版年
2024年 | 1篇 |
2023年 | 2篇 |
2022年 | 11篇 |
2021年 | 13篇 |
2020年 | 10篇 |
2019年 | 19篇 |
2018年 | 20篇 |
2017年 | 25篇 |
2016年 | 19篇 |
2015年 | 17篇 |
2014年 | 14篇 |
2013年 | 35篇 |
2012年 | 22篇 |
2011年 | 23篇 |
2010年 | 25篇 |
2009年 | 9篇 |
2008年 | 23篇 |
2007年 | 29篇 |
2006年 | 29篇 |
2005年 | 31篇 |
2004年 | 17篇 |
2003年 | 16篇 |
2002年 | 11篇 |
2001年 | 4篇 |
2000年 | 2篇 |
1999年 | 4篇 |
1998年 | 2篇 |
1997年 | 2篇 |
1996年 | 2篇 |
1995年 | 1篇 |
1994年 | 1篇 |
1993年 | 3篇 |
1992年 | 1篇 |
1990年 | 3篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1984年 | 1篇 |
1983年 | 2篇 |
1982年 | 2篇 |
1981年 | 6篇 |
1978年 | 1篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1936年 | 1篇 |
1931年 | 1篇 |
排序方式: 共有464条查询结果,搜索用时 15 毫秒
461.
Irene E.G. van Hellemond Carolien H. Smorenburg Petronella G.M. Peer Astrid C.P. Swinkels Caroline M. Seynaeve Maurice J.C. van der Sangen Judith R. Kroep Hiltje de Graaf Aafke H. Honkoop Frans L.G. Erdkamp Franchette W.P.J. van den Berkmortel Maaike de Boer Wilfred K. de Roos Sabine C. Linn Alexander L.T. Imholz Vivianne C.G. Tjan-Heijnen 《International journal of cancer. Journal international du cancer》2019,145(5):1325-1333
The phase III DATA study investigates the efficacy of adjuvant anastrozole (6 vs. 3 year) in postmenopausal women with breast cancer previously treated with 2–3 years of tamoxifen. This planned side-study assessed patterns of care regarding detection and treatment of osteopenia/osteoporosis, and trends in bone mineral density (BMD) during and after therapy. We registered all BMD measurements and bisphosphonate-use. Time to osteopenia/osteoporosis was analysed by Kaplan Meier methodology. For the trend in T-scores we used linear mixed models with random patients effects. Of 1860 eligible DATA patients, 910 (48.9%) had a baseline BMD measurement. Among patients with a normal baseline BMD (n = 417), osteopenia was observed in 53.5% and 55.4% in the 6- and 3-year group respectively (p = 0.18), during follow-up. Only two patients (3-year group) developed osteoporosis. Of the patients with osteopenia at baseline (n = 408), 24.4% and 20.4% developed osteoporosis respectively (p = 0.89). Three years after randomisation 18.3% and 18.2% used bisphosphonates in the 6- and 3-year groups respectively and 6 years after randomisation this was 23.7% and 20.9% respectively (p = 0.90) of which the majority used oral bisphosphonates. The yearly mean BMD-change during anastrozole in the lumbar spine showed a T-score decline of 0.075. After bisphosphonate addition the decline became less prominent (0.047 (p < 0.001)) and after anastrozole cessation, while continuing bisphosphonates, the mean BMD yearly increased (0.047 (p < 0.001)). In conclusion, extended anastrozole therapy was not associated with a higher incidence of osteoporosis. Anastrozole-use was associated with a BMD decrease; however, the decline was modest and partially reversible after anastrozole cessation. 相似文献
462.
Atkinson JM Shelat AA Carcaboso AM Kranenburg TA Arnold LA Boulos N Wright K Johnson RA Poppleton H Mohankumar KM Féau C Phoenix T Gibson P Zhu L Tong Y Eden C Ellison DW Priebe W Koul D Yung WK Gajjar A Stewart CF Guy RK Gilbertson RJ 《Cancer cell》2011,20(3):384-399
Using a mouse model of ependymoma-a chemoresistant brain tumor-we combined multicell high-throughput screening (HTS), kinome-wide binding assays, and in?vivo efficacy studies, to identify potential treatments with predicted toxicity against neural stem cells (NSC). We identified kinases within the insulin signaling pathway and centrosome cycle as regulators of ependymoma cell proliferation, and their corresponding inhibitors as potential therapies. FDA approved drugs not currently used to treat ependymoma were also identified that posses selective toxicity against ependymoma cells relative to normal NSCs both in?vitro and in?vivo, e.g., 5-fluorouracil. Our comprehensive approach advances understanding of the biology and treatment of ependymoma including the discovery of several treatment leads for immediate clinical translation. 相似文献
463.
464.
Manders P Tjan-Heijnen VC Span PN Grebenchtchikov N Geurts-Moespot A van Tienoven DT Beex LV Sweep FC 《Cancer》2004,101(3):486-494
BACKGROUND: The ability of a solid tumor to grow and metastasize has a significant dependence on protease systems, such as the plasminogen activation system. The plasminogen activation system includes the urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1), among other molecules. Both uPA and PAI-1 are established prognostic factors for patients with breast carcinoma. In the current study, the authors investigated whether the complex of uPA with PAI-1 is also associated with the natural course of this malignancy. METHODS: Cytosolic levels of uPA, PAI-1, and the uPA:PAI-1 complex were measured in tumor tissue from 576 patients with lymph node-negative invasive breast carcinoma using quantitative enzyme-linked immunosorbent assays. Patients did not receive adjuvant systemic therapy, and the median follow-up duration was 61 months (range, 2-187 months) after primary diagnosis. Correlations with well known clinicopathologic factors were assessed, and univariate and multivariate survival analyses were performed. RESULTS: uPA:PAI-1 complex levels were positively associated with adverse histologic grade and inversely correlated with estrogen and progesterone receptor status. On univariate analysis, increased levels of the uPA:PAI-1 complex were found to be associated with reduced recurrence-free survival (RFS) and overall survival (OS) rates. On multivariate analysis, uPA:PAI-1 complex levels were found to be an independent predictor of OS (P = 0.039), but not RFS (P = 0.240). When uPA and PAI-1 levels were not included in the multivariate analysis, uPA:PAI-1 complex levels became a significant predictor of both RFS and OS (P = 0.029 and P = 0.007, respectively). CONCLUSIONS: The results of the current study demonstrate that uPA:PAI-1 complex levels have prognostic value on univariate analysis. In addition, increased uPA:PAI-1 complex levels were significantly associated with poor OS on multivariate analysis. Increased uPA:PAI-1 complex levels were also significantly associated with reduced RFS rates after the exclusion of uPA and PAI-1 levels from the multivariate analysis model. 相似文献